| Phosphodiesterases (PDEs), enzymes that degrade 3′,5′-cyclic nucleotides, are being pursued as therapeutic targets for several diseases, including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metabolism. Clinical development programmes have focused exclusively on catalytic inhibition, which continues to be a strong focus of ongoing drug discovery efforts. However, emerging evidence supports novel strategies to therapeutically target PDE function, including enhancing catalytic activity , normalizing altered compartmentalization and modulating post-translational modifications, as well as the potential use of PDEs as disease biomarkers. Importantly, a more refined appreciation of the intramolecular mechanisms regulating PDE function and trafficking is emerging, making these pioneering drug discovery efforts tractable.
Conventional 3′,5′-cyclic nucleotide phosphodiesterases (PDEs) are members of a highly conserved superfamily of enzymes that degrade the canonical cyclic nucleotides 3′,5′-cAMP and 3′,5′-cGMP 1 , as well as the noncanonical cyclic nucleotides 3′,5′-cCMP, 3′,5′-cUMP, 3′,5′-cIMP and c-di-GMP 2-4 ( Fig. 1 ). As extensively reviewed elsewhere 1 , there are 11 families of PDEs that are grouped based on the homology of their C-terminal catalytic domain, and each PDE family has multiple isoforms that differ in terms of the length and complexity of their N-terminal regulatory domains (Fig. 2 ). PDEs do not simply control the total cellular content of cyclic nucleotides, but rather create individual pockets or nanodomains of cyclic nucleotide signalling. It is this subcellular compartmentalization of cyclic nucleotide signalling that enables a single cell to respond discretely to multiple extracellular and intracellular signals. Thus, PDEs regulate a myriad of physiological processes, and their dysfunction has been associated with numerous pathophysiological states including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metabolism (Box 1). Because the location of a PDE is just as important to its overall function as its catalytic activity, how the location of a given PDE isoform can change based on tissue type, age or disease status -possibly due to factors such as activation of receptors, alterations in calcium signalling or elevations in cyclic nucleotides -is of paramount importance when considering the therapeutic potential of a given PDE isoform (for example, see reFs [5] [6] [7] [8] [9] [10] [11] [12] ; for a full review, see Supplementary Table 1 ). Importantly, no two PDE isoforms share the exact same combination of substrate specificity, tissue expression profile and subcellular localization (Supplementary Table 1 ). This is quite important because there are several diseases in which compartment-specific defects in cyclic nucleotide signalling have been identified. For example, the function of soluble guanylyl cyclase, but not particulate guanylyl cyclase, is substantially impaired in brains of patients with Alzheimer disease (AD) and in in vitro models of AD pathology [13] [14] [15] , which would be expected to decrease cytosolic pools of cGMP. In contrast, in colon cancer, membrane-bound guanylyl cyclase appears to be dysregulated/suppressed 16 and membrane-enriched PDE10A appears to be overexpressed 17 , both of which would decrease membrane-proximal pools of cGMP. That said, cytosolic pools of cGMP may also be decreased in colorectal cancer cells, as PDE5A is also overexpressed in these cells 17 , and -at least in the heart and brain -PDE5 regulates pools of cGMP that are downstream of soluble guanylyl cyclases 18, 19 .
With regard to compartment-specific changes in cAMP signalling, studies examining brain tissue from patients with bipolar disorder show no change in the membrane but increased signalling in the cytosol, which may be normalized by the classic mood stabilizer lithium (for example, see reFs 20, 21 ). Other disease states where compartment-specific defects in cyclic nucleotide signalling have been implicated include -but are not limited to -erectile dysfunction 22 , hypertension 23 , cardiac hypertrophy 18, 24 , acrodysostosis 25, 26 and Huntington disease 27, 28 . The unique substrate/localization profile offered by each Nanodomains subcellular compartments within which intracellular signalling is discretely localized largely due to anchoring of molecules within macromolecular complexes.
Acrodysostosis
A rare congenital disorder characterized by abnormal bone growth leading to very short fingers/toes, underdeveloped facial bones, a small nose and short stature, as well as developmental and intellectual disabilities.
Therapeutic targeting of 3 ′ ,5 ′ -cyclic nucleotide phosphodiesterases: inhibition and beyond PDE isoform offers multiple degrees of freedom in the context of therapeutic targeting. As such, isoform-specific targeting could enable selective restoration of cyclic nucleotide signalling in affected compartments (that is, provide efficacy) without disturbing cyclic nucleotide signalling elsewhere (that is, avoid side effects).
As reviewed in detail below, there has been and continues to be strong interest in developing PDE-targeted therapeutics for numerous diseases. Unfortunately, the majority of PDE-targeted therapeutics on the market are simply competitive blockers of substrate binding at the catalytic site that lack the ability to selectively target a specific isozyme within a single PDE family or subfamily. That said, novel therapeutic strategies are currently being explored to increase the selectivity and specificity with which PDEs are targeted (for example, by targeting protein-protein interactions). Further, PDE activators are now being considered as agents for treating select diseases, as is the exploitation of PDEs as biomarkers for diagnosis and/or patient selection (Box 2). Here, we review the clinical successes and failures of PDE inhibitors to date and describe several ways in which the field is moving beyond pharmacological inhibition of PDEs for therapeutic gain. This review largely focuses on PDE function as it relates to the canonical cyclic nucleotide substrates, cAMP and cGMP, because little is known about the pathophysiology of non-canonical cyclic nucleotides and what is known has been recently reviewed elsewhere 4 .
Therapeutic PDE inhibition
Several PDE family-selective inhibitors have successfully reached the market, targeting diseases such as psoriasis, chronic obstructive pulmonary disorder (COPD) and erectile dysfunction (TABle 1) . Conversely, many potent and selective PDE inhibitors have failed when tested in clinical trials (TABle 2) . Below, we will summarize the main achievements and pitfalls in the development of marketed PDE inhibitors to consider factors that currently limit the effectiveness of such therapeutic agents. cAMP is synthesized by transmembrane adenylyl cyclases (tACs) that are activated by Gα s and inhibited by Gα i 318 as well as soluble adenylyl cyclases (sACs) that are activated by bicarbonate and calcium 319 . cGMP is synthesized by particulate guanylyl cyclases (pGCs) that are activated by natriuretic peptides (NPs) and soluble guanylyl cyclases (sGCs) that are activated by nitric oxide (NO) 320 . Both cAMP and cGMP activate cyclic nucleotide gated channels (CNGs) and allosterically modulate the activity of select phosphodiesterases (PDEs) 199 . In contrast, only cGMP stimulates protein kinase G (PKG), whereas cAMP activates protein kinase A (PKA), exchange protein activated by cAMP (Epac) and popeye domain-containing (POPDC) proteins 321 . Signalling through either the cAMP or cGMP pathways ultimately leads to phosphorylation of a myriad of downstream targets, including the transcription factor cAMP response element binding protein (CREB). In addition to cAMP and cGMP, several PDEs also hydrolyse the non-canonical cyclic nucleotides (not included) cUMP (PDE3A , PDE3B, PDE9A), cCMP (PDE7A) and c-di-GMPa (bacterial PDEs), albeit with much lower affinity 2, 3 . GPCR , G protein-coupled receptor.
Given the clinical successes of some PDE inhibitors as discussed, traditional PDE inhibitors are still very much being pursued as potential therapeutics, particularly in the context of the central nervous system (CNS), the cardiovascular system, the reproductive system, cancer and metabolic disorders (TABle 3) .
Marketed PDE inhibitors
The non-selective PDE1 inhibitor vinpocetine is not US Food and Drug Administration (FDA) approved but is available in over-the-counter supplements (for example, Cavinton or Intelectol, Richter Gedeon; Cognitex, Life Extension) claiming to improve memory and recovery from stroke, likely due to increasing vasodilation 29 . As extensively reviewed elsewhere 29 , numerous clinical trials have examined the cognition-enhancing effects of vinpocetine -either alone or in combination with another compound (for example, caffeine or Ginko biloba) -and have generally found improvement in healthy volunteers, individuals with cerebral hypofusion and possibly aged individuals, but no improvement in patients with AD. Reports of side effects associated with vinpocetine have generally been minimal 30 (TABle 1) .
Several PDE3 inhibitors are currently marketed, with cilostazol and milrinone perhaps the most widely known. Cilostazol received FDA approval in 1999 for intermittent claudication, but off-label uses include secondary prevention of cerebrovascular accident, percutaneous coronary intervention and coronary stent stenosis 31 . Cilostazol improves function across several domains, but is associated with serious side effects (TABle 1) and, thus, is contraindicated for patients with severe heart failure, hepatic impairment or renal impairment 32 . Milrinone increases contractility of the heart and is FDA approved for short-term management of severe congestive heart failure. It is particularly used in the context of end-stage heart failure for patients who prove resistant to optimal therapy and for those awaiting cardiac transplant 33 . That said, the clinical utility of milrinone has been limited by significant side effects (TABle 1) and the fact that it is cleared through the kidneys (that is, generally not used in patients with renal failure) 33 .
Three so-called 'second-generation' PDE4 inhibitors are currently FDA approved, with a fourth compound marketed as an over-the-counter supplement. Roflumilast is an add-on therapy for COPD (TABle 1) . Although it causes gastrointestinal and weight-loss side effects, making it a third-line treatment for COPD, roflumilast improves sugar metabolism in obese patients and may decrease cardiovascular events in patients with COPD 34 . Apremilast is used in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [35] [36] [37] Cerebral hypofusion reduces blood flow to/throughout the brain.
Coronary stent stenosis
A gradual re-narrowing of a coronary artery leading to restricted blood flow that occurs after angioplasty and stenting have been performed to relieve a prior blockage.
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PDE1A,B,C cAMP/cGMP and is also being tested in a phase IV trial for active ankylosing spondylitis (see below). The most common side effects for both of these orally administered PDE4 inhibitors are the same as those that plagued first-generation PDE4 inhibitors (that is, gastrointestinal disturbances ; TABle 1) , albeit with much improved therapeutic windows 35 . Crisaborole is a topically applied ointment for treatment of moderate atopic dermatitis in patients >2 years old. Given the topical nature of the drug, gastrointestinal side effects are avoided and, instead, hypersensitivity reactions are the major possible side effect. Clearly, there is an anti-inflammatory theme shared among these FDA-approved PDE4 inhibitors. Zembrin is a non-selective PDE4 inhibitor (also acts as a 5-hydroxytryptamine uptake inhibitor) that is a component of numerous herbal supplements claiming calming or mood-stabilizing properties (for example, Calm, Doctor's Best; Mood, Procera; Nutri-calm, Nature's Sunshine) 38 . Functional magnetic resonance imaging of the amygdala in humans supports an anxiolytic-like effect of Zembrin 38 . Further, a phase I trial found that Zembrin was well tolerated and improved cognitive flexibility, executive function, mood and sleep 39 . Numerous PDE4 inhibitors are currently being pursued to improve cognitive functioning (see below). There are four PDE5 inhibitors currently FDA approved and marketed in the USA, with two additional PDE5 inhibitors marketed outside the USA. All six PDE5 inhibitors were originally marketed for erectile dysfunction (TABle 1) , with the most recent approval for avanafil based on its much more rapid onset of action. Sildenafil later received secondary approval for pulmonary hypertension (contraindicated for paediatric patients, veno-occlusive disease or sickle cell disease), as did tadalafil. These PDE5 inhibitors are generally considered safe and well tolerated, with no increase in cardiac mortality or myocardial infarction 40 . They share largely similar side-effect profiles (TABle 1) , with headache, flushing, dyspepsia and vision disturbances being the most common adverse events 40 . Interestingly, udenafil (Zydena, Mezzion Pharma) -one of the PDE5 inhibitors used to treat erectile dysfunction in Korea, Russia and Philippines 41,42has also been reported to improve cognitive function in patients with erectile dysfunction 43, 44 .
The success of several marketed PDE inhibitors validates PDEs as appropriate therapeutic targets in many pathological conditions. However, the presence of unwanted side effects resulting from the inability to target individual isoforms is the major limiting factor to success. It is notable that of the 11 PDE families, only agents that attenuate the activity of PDEs 1, 3, 4 and 5 have made it to market, despite significant efforts targeting the inhibition of other PDE families (see next).
Failed PDE inhibitor clinical trials
Despite the successes noted above, numerous PDE inhibitors that entered the clinic failed to make it to market. The selective PDE2 inhibitor PF-05180999 was originally considered a candidate for cognitive impairments associated with schizophrenia based on its preclinical profile 45 ; however, it was brought into the clinic for migraine. Even with the completion of earlier phase I safety and tolerability studies, additional trials were terminated early due to safety concerns (TABle 2) . Exisulind inhibits both PDE2A and PDE5A (which are overexpressed in numerous precancerous and cancerous cell types) and triggers apoptosis in precancerous/cancerous cells with minimal effects on healthy cells 46, 47 . Despite promising findings in multiple clinical trials, exisulind failed to secure FDA approval due to deficiencies in safety and efficacy 46, 47 (TABle 2) .
As noted above, cilastozol has gained FDA approval for intermittent claudication; however, clinical trials for other indications, such as type 2 diabetes mellitus peripheral neuropathy, have failed 48 . That said, cilostazol significantly improved walking speed in these patients, suggesting improved peripheral blood flow as would be expected based on its current approved indication 48 .
The PDE4 inhibitor cilomilast (Ariflo, GlaxoSmith-Kline) gained FDA approval in 2003 as a second-line treatment for COPD in patients who are poorly responsive to salbutamol 49 . However, cilomilast never made it to market due to the severely dose-limiting nature of
Box 1 | Physiological roles of PDEs
Because phosphodiesterases (PDEs) are ubiquitously distributed and are the only enzymes to degrade 3′,5′-cyclic nucleotides, this superfamily of enzymes plays a role in numerous biological processes in health and disease. That said, the biological roles played by a given PDE isoform are distinct due to its unique expression pattern at the level of tissue/organ, cell type and subcellular compartment ( Supplementary Table 1 ).
most PDE families are expressed in the nervous system where they regulate neurodevelopment and apoptosis, neuronal excitability, synaptic transmission and neuroplasticity 71, 96 . Every brain region expresses more than one PDE, but no two PDEs exhibit the exact same regional distribution 71 . For instance, PDE11A is the only PDE with brain expression restricted to the hippocampus. While PDE11A regulates how well an individual responds to the mood stabilizer lithium, it does not regulate basal anxiety and depression-related behaviours 177 . In contrast, PDE4D is expressed in most brain regions and does appear to regulate basal depression-related behaviours (for example, see reF. 296 ). PDE1B, PDE2A, PDE7B, PDE8B and PDE10A are enriched in the striatum relative to other brain regions 71 and each has been implicated in regulating basic motor function, whereas PDE5A and PDE9A that are enriched in the cerebellum have not (for a review, see reFs 71, 297 ). In the retina, PDE6 function is central in mediating activation of the light response in rod and cones photoreceptors, and PDE6 mutations cause photoreceptor degeneration in retinitis pigmentosa 227, 298 .
In the cardiovascular system, PDE2, PDE3 and PDE4 isoforms control different subcellular pools of cyclic nucleotides to regulate important cardiac functions from myocardial contraction/relaxation to chronic cell growth and survival, and disruption of this PDE signalling has been associated with disease (for a review, see reF. 1 ). For example, heart failure has been associated with reduced levels of PDE3A and PDE4D, which results in myocyte apoptosis and cardiac arrhythmias, respectively 225, 239 .
many cancers have been associated with reduced levels of cAmP and/or cGmP secondary to an elevation in PDE activity. For example, chronic lymphocytic leukaemia cells exhibit increased PDE7B expression; leukaemia, colon cancer and glioma cells overexpress one or more isoforms of PDE4; and colon cancer cells and adenocarcinomas exhibit elevated PDE5 activity 16, 299, 300 .
Inflammation of numerous tissue types can be enhanced by a drop in cAmP levels that is caused by an increase in cAmP-PDE activity. For example, activity of PDE4the predominant cAmP-hydrolysing enzyme in the immune system -is elevated in the context of various inflammatory diseases, including psoriasis, chronic obstructive pulmonary disorder and asthma 301, 302 .
PDEs are also implicated in reproductive health. Several isoforms are present in granulosa cells as well as in oocytes in preovulatory follicles of the mammalian ovary regulating the meiotic cell cycle 303 . Furthermore, many PDEs are expressed in cells of the spermatogenic pathway where they may regulate sperm motility 304, 305 , and PDE5 is expressed in the contractile tissues of the male excurrent tract and accessory where its increased activity contributes to erectile dysfunction (for example 23 ).
gastrointestinal side effects (for example, nausea and vomiting, diarrhoea and abdominal pain 35 ). The fact that cilomilast elicited more pronounced side effects relative to the other systemically delivered PDE4 inhibitors described above may be related to preferential inhibition of the PDE4D family relative to the other PDE4 subtypes 49 . The novel PDE4 inhibitor ASP9831 was tested in phase I and II trials for non-alcoholic steatohepatitis based on preclinical findings, but failed to improve biochemical biomarkers of the disease 50 . As target engagement in the organ of interest was not confirmed 50 , the reasons underlying the lack of efficacy remain unclear.
Several clinical trials have attempted to extend therapeutic indications for PDE5 inhibitors but failed. As reviewed extensively elsewhere 29 , numerous trials have tested the effects of sildenafil or vardenafil on various measures of cognition in healthy volunteers or patients with schizophrenia and have largely found no effects [51] [52] [53] [54] [55] . That said, one report from an Iranian clinical trial did report an improvement in negative symptoms in patients with chronic schizophrenia when sildenafil was administered in addition to risperidone 56 . Several studies were initiated to study sildenafil and/or tadalafil in patients with Duchenne or Becker muscular dystrophy, with the hope that the vasodilatory properties of the drugs would improve muscular ischaemia; however, clinical trial outcomes have been mixed 57, 58 (TABle 2) .
Two PDE9 inhibitors have been tested in the clinic for cognition-enhancing effects. Although PF-04447943 was found to be safe and well tolerated, it failed to improve either cognition or dementia-related behavioural disturbances in a phase II clinical trial 59 . Similarly, BI 409306 was reported as safe and well tolerated in healthy subjects as well as in patients with AD or schizophrenia; however, no positive effects on cognition were observed in either patient population [60] [61] [62] [63] [64] . BI 409306 is still being tested in the clinic for prevention of schizophrenia relapse and prevention of first psychotic episode (TABle 3 ). The failure of PDE9 inhibitors to improve functioning in AD may be related to the fact that brain PDE9A is enriched in the nucleus and membrane 5 and, thus, is not in a position to directly regulate the cytosolic pools of cGMP that appear to be dysregulated in AD [13] [14] [15] .
Numerous clinical trials have tested the PDE10 inhibitor PF-02545920 in schizophrenia and Huntington disease (TABles 2,3). Despite widely replicated efficacy in several preclinical assays (for example, see reFs 65, 66 ), PF-02545920 failed to improve symptoms in patients with either exacerbated, stable or suboptimally treated schizophrenia 67 (TABle 2) . Further, in at least one trial, there were reports of motoric side effects such as dystonia 67 . Similarly, despite decreased striatal expression of PDE10A being found in patients with Huntington disease (Box 2) and promising efficacy of PDE10 inhibitors in preclinical models of the disease 28, 68, 69 , PF-02545920 failed to improve symptoms in patients with Huntington disease (NCT02197130; accessed 28 May 2019), and so efforts for this disease indication were terminated (NCT02342548; accessed 28 May 2019). Several other PDE10 inhibitors have also been pursued in the clinic for schizophrenia and/or Huntington disease, with some efforts subsequently suspended or terminated (TABle 2) and others ongoing (TABle 3; see more below).
The unsuccessful translation of these PDE inhibitors from promising preclinical data to human testing suggests that therapeutic approaches targeting PDEs need to extend beyond occlusion of the enzyme's catalytic site. Of particular note are the numerous failures seen in nervous system disorders, even when target engagement was verified. Expression of PDEs in the brain is particularly complex, with PDE isoforms differentially expressed across circuits, cell types and subcellular domains 5, 30, 70, 71 . Thus, the challenge in evaluating the clinical potential for the next generation of PDE-modulating drugs is to gain novel insights about disease-related changes in PDE structure, function and regulation to understand how PDEs should be targeted in a compartment-specific manner for therapeutic gain.
PDE inhibitors in development
Ongoing efforts in the development of novel PDE inhibitors include creation of new chemical entities as well as the repurposing of existing entities. Advances in our understanding of structural differences that exist between PDEs, coupled with extensive medicinal Dystonia A movement disorder characterized by repetitive or twisting movements due to involuntary muscle contraction.
Box 2 | PDEs as disease biomarkers
Phosphodiesterases (PDEs) are also being explored as both diagnostic and patient-selection biomarkers. This superfamily of enzymes, like other genes, can be genotyped from blood samples to assess risk for specific diseases (for example, high suicide risk 306 ; PDE8A, NCT02855918). PDE mRNA and protein expression can be measured ex vivo in an isoform-specific manner from biopsied samples (for example, excised tumours). Further, imaging compounds can be engineered with relative ease to selectively target a given PDE family/subfamily in vivo. Thus, PDEs can be explored as biomarkers in diseases where tissue is readily biopsied (for example, cancers) and in diseases where tissue is not (for example, diseases of the brain).
Ex vivo biomarkers
measurement of PDE4D7 is seen as a valuable biomarker for both pre-surgical and post-surgical risk stratification to optimize prostate cancer treatment decisions 306, 307 (TABle 4 ). Studies in patient samples showed that PDE4D7 expression is initially upregulated with the development of primary tumours but then is downregulated when the disease progresses to an androgen-independent state (for example, in castration-resistant tumours) 308, 309 , consistent with in vitro reports using prostate cancer cells 193 . The analysis of PDE4D7 expression in biopsy/surgery samples has been applied to develop InformmDx (licensed by mDxHealth from Philips), a tissue-based prognostic prostate cancer biomarker test to stratify patients by risk of disease progression and secondary tumours and, thus, inform post-biopsy/post-surgery treatment decisions 310 .
PDE3A may also represent a useful cancer biomarker as it is greatly expressed in certain cancer cell types such as squamous carcinoma cell lines or gastrointestinal stromal tumour cells 311, 312 . Furthermore, cancer cell lines with the highest PDE3A expression proved the most susceptible to the chemotherapeutic effects of PDE3 inhibitors 313 . Thus, PDE3A expression could qualify as a biomarker for patient selection which improves patient care by reducing exposure to ineffective drugs and accelerates clinical development of novel therapeutic agents by testing them in targeted populations.
In vivo biomarkers
Altered cyclic nucleotide signalling has been implicated in various age-related diseases of the brain 238 . PDE10A is widely reported as downregulated in both the striatum and the cortex of patients with Huntington disease, with the extent of PDE10A loss corresponding to the genetic burden associated with the disease 28, 68, 314, 315 . A loss of PDE10A expression has also been observed in the basal ganglia of patients with Parkinson disease 316 . Importantly, highly-specific PDE10A positron emission tomography (PET) tracers show that PDE10A expression in patients with Huntington disease continues to decline over years 28 . Thus, PET imaging of PDE10A could be a useful biomarker for assessing the initial diagnosis and subsequent progression of these neurodegenerative diseases 27 . PET ligands also exist for PDEs 2, 4, 5 and 7 (reF. 317 ).
www.nature.com/nrd chemistry efforts to optimize structure-activity relationships, have yielded recent vast improvements in terms of selectivity and potency (for example, see work related to PDE10 inhibitors and PDE4 inhibitors [72] [73] [74] ). These efforts have also yielded PDE inhibitors with novel modes of action in some cases (that is, acting as a negative allosteric modulator instead of a direct catalytic inhibitor 73 ). In addition, there are still significant efforts to repurpose older PDE inhibitors. Drug-repurposing efforts can be driven by computational or experimental approaches; however, most drug-repurposing efforts have been driven either by a better understanding of pharmacology or by a retrospective analysis of clinical effects that were observed during trials or marketed use of a drug for its original indication 75 . Indeed, the PDE5 inhibitor sildenafil was originally brought into clinical trials for angina but -following observations made by clinicians in that trial -was later repurposed for erectile dysfunction. Drug repurposing has several advantages including reduced risk and substantially reduced timelines and cost due to the fact that the drug would already have passed preclinical and phase I safety testing, and possibly even formulation development 75 . That said, there are numerous barriers to recouping expenses incurred by drug-repurposing trials, particularly when they are carried forward by an entity other than the patent holder or following the expiration of the original patent (see reF. 75 for further discussion).
Non-selective inhibitor. The non-selective PDE3, 4, 10 and 11 inhibitor Ibudilast, which also inhibits glial cell activation, is approved for use in Japan as a bronchodilator and has long been of interest as a therapeutic approach for neuropathic pain and substance abuse/ withdrawal 76, 77 . Recent clinical trials have tested Ibudilast in the context of amyotrophic lateral sclerosis and pain, as well as opiate, methamphetamine and alcohol abuse (TABle 3) , and positive effects have been reported for all trials completed to date [78] [79] [80] [81] .
PDE1 inhibitors.
The broad PDE1 inhibitor ITI-214, which shows picomolar half-maximal inhibitory concentration (IC 50 ) values for PDE1A, PDE1B and PDE1C in enzymatic assays and >1000-fold selectivity versus its nearest neighbour PDE4 (reFs 82,83 ), is being explored for CNS and non-CNS indications. ITI-214 demonstrates cognition-enhancing effects in rodent models of long-term memory and working memory deficits [82] [83] [84] , mimicking effects of a dopamine 1 receptor (D1R) agonist 84 and occurring at doses that leave efficacy of the antipsychotic risperidone intact 82 . Although the target mediating the cognition-enhancing effects of ITI-214 remains undetermined, PDE1B may be the most likely candidate given its expression in D1R-expressing neurons 84 , along with the fact that a PDE1B-selective inhibitor showed similar cognition-enhancing effects 85 . ITI-214 was moved into the clinic, with potential applications for cognitive deficits associated with schizophrenia, AD and Parkinson disease 83 , with safety and tolerability established in healthy volunteers and patients with schizophrenia (TABle 3) . ITI-214 is also being explored in the clinic for heart failure (NCT03387215)
given its ability to improve cardiac function in dog and rabbit models of heart failure 86 as a consequence of its inhibition of PDE1C 86 . 87 . TAK-915 entered phase I trials to correlate plasma exposures with central target engagement, with the purpose of informing dose selection for future trials targeting cognitive impairment in schizophrenia [88] [89] [90] (TABle 3) . Looking beyond the brain, PDE2 inhibitors may hold relevance for cardiovascular function as elevated PDE2A expression has been found in failing human hearts as well as a large number of animal models of heart disease 91 . Further, PDE2 inhibitors may hold promise as an antifungal treatment for moderate to severe candidiasis infections, given that genetic deletion of Pde2a reduces virulence and biofilm integrity of the fungal pathogen 92 .
PDE2 inhibitors. Several highly selective PDE2 inhibitors have demonstrated cognition-enhancing, anxiolytic and antidepressant-like effects in animal models
PDE3 inhibitors.
Despite its existing FDA approval, the efficacy and safety of cilostazol is still very much a topic of investigation, with 27 active clinical trials registered on ClinicalTrials.gov (accessed 30 April 2019) and 54 more drawn to a close within just the past 10 years. Numerous recent phase IV studies appear focused on broadening the therapeutic indications of cilostazol to include vasculature-related insults and nephropathies associated with type 2 diabetes (TABle 3) , and recent reports suggest largely positive effects 31, 48, 93, 94 . This PDE3 inhibitor also elicited some improvement in chronic tinnitus 95 . Several prospective and retrospective studies have examined cilostazol as a primary or adjunctive treatment for cognitive deficits associated with AD and schizophrenia; the majority of which demonstrated positive effects on cognition (see reF. 29 for a review). The mechanism by which cilostazol elicits improved cognition has yet to be determined empirically. Given that there is very little expression of PDE3A or PDE3B in the brain 71, 96 , it may be likely that the cognition-enhancing effects of cilostazol are driven by increased cerebral blood flow that comes with chronic -but not acute -dosing as opposed to inhibition of PDE3 isoforms directly in the brain (for example, see reF. 97 ).
Novel therapeutic applications of cilostazol are also being explored in preclinical studies. For example, oral cilostazol improved retinal stress, ischaemia and ganglion cell death in a rat model of diabetic retinopathy 98 . In addition, Pde3a-knockout mice are infertile 99 and chronic administration of cilostazol blocks pregnancy in naturally cycling swine 100 , suggesting potential utility of PDE3 inhibitors for birth control or regulating in vivo oocyte maturation in the context of assisted reproduction. Indeed, administration of cilostazol to superovulated mice improved in vitro fertilization rates of subsequently harvested oocytes, possibly by virtue of synchronizing the oocyte maturation 101 .
Due to the promise of PDE3 as a therapeutic target, coupled with concerns over side effects associated with cilostazol, alternative PDE3 inhibitors are currently being developed [102] [103] [104] . (TABle 3) . Interestingly, a recent case report showed that apremilast dramatically improved repigmentation in a woman with treatment-resistant vitiligo 105 . Multiple case reports have also described an ability of apremilast to improve symptoms in patients with treatment-resistant erosive oral lichen planus [106] [107] [108] , perhaps motivating the recently registered phase II study that will test the ability of apremilast to improve genital erosive lichen planus (TABle 3) . Additional indications are also being explored for roflumilast. Phase IV studies showed that roflumilast reduced fat mass and, thus, body weight in obese women with polycystic ovary syndrome; however, these reductions were smaller than those elicited by liraglutide 109, 110 (TABle 3) . The PDE4 inhibitor TAK-648 is being tested in the clinic in patients with type 2 diabetes, based on preclinical data 111 . Roflumilast has also been tested for its ability to improve cognition and information processing in healthy humans, with promising results observed at a dose previously indicated as being devoid of side effects 112 . Patients with stabilized schizophrenia receiving adjuvant roflumilast in a small phase II trial showed no improvement in working memory but did show some improvement in verbal learning and memory 113 . Given these positive findings, roflumilast was tested in elderly subjects who demonstrated no change in spatial memory but improved verbal word memory with roflumilast treatment 114 . Numerous preclinical studies have supported the therapeutic potential of PDE4 inhibitors in the context of schizophrenia and cognition [115] [116] [117] [118] .
Cognition-enhancing effects have also been reported for the PDE4 inhibitor HT-0712, which improved long-term memory for word lists without serious adverse events in elderly subjects experiencing cognitive decline 119 . The cognition-enhancing effect of HT-0712 in humans is consistent with previous reports in mice 120, 121 . The PDE4D negative allosteric modulator BPN14770 is also being pursued for improving cognitive impairment and has been tested for safety and/or efficacy in healthy elderly subjects, in healthy volunteers with scopolamine-induced cognitive impairment and in adult males with fragile X syndrome (TABle 3) . In a press release, BPN14770 was described as having good safety and oral bioavailability and an ability to improve
Lichen planus
An inflammatory condition characterized by purplish, itchy bumps on/around the skin, hair, nails and mucous membrane (due to unknown causes). working memory in healthy elderly adults 122 . These effects in humans are consistent with preclinical studies showing that BPN14770 improved numerous behaviours in a mouse model of fragile X syndrome and antagonized the amnestic effects of scopolamine in mice 123, 124 .
NATuRE REvIEWS | DrUg DISCovEry
Based on preclinical studies showing anxio lytic and cognition-enhancing effects 125 , the PDE4 inhibitor GSK356278 entered phase I safety trials for Huntington disease but adverse events limited the highest dose to that achieving only ~50% occupancy in the brain 125 (TABle 3 ). Other nervous system dis orders for which preclinical evidence suggests a therapeutic potential of PDE4 inhibitors include ischaemic stroke 120,126-129 , traumatic brain injury 130 , axon regener ation 131 and substance abuse disorders (both causes and consequences [132] [133] [134] [135] ).
McCune-Albright syndrome is a disease affecting endocrine tissues, skin and bones and is caused by a mutation that results in constitutive activation of the G-protein α-subunit Gα s (Gα s *). Preclinical studies show that whereas Gα s * triggers increased cAMP levels in some tissues, it actually results in decreased cAMP levels in other tissues due to a protein kinase A (PKA)-dependent upregulation of PDE activity, particularly that of PDE1 and PDE4 (reFs 116, 136, 137 ). Consistent with this upregulation of PDE4 activity, the PDE4 inhibitor rolipram was able to reverse deficits in Gα s mouse models 116, 117 . A clinical trial measuring PDE4 expression in the brain and peripheral organs of patients with McCune-Albright syndrome is currently underway (TABle 3) .
More recent work examined PDE4 in the context of cancer. Both preclinical and clinical data suggest that roflumilast may exhibit antitumor activity for B cell lymphomas 138 . The PDE4 inhibitor rolipram, in combination with cAMP-elevating agents, has been shown to suppress triple-negative breast cancer both in vitro and in vivo in mice 139 . Apremilast similarly induced tumour regression in mouse models of colorectal cancer 140 . Perhaps even more interesting, specific inhibition of PDE4D, either with genetic tools or the PDE4D inhibitor Gebr-7b, resensitized chemotherapy-resistant oestrogen receptor-positive breast cancer cells 141 . These early studies provide promise for the chemotherapeutic potential of PDE4 inhibitors.
PDE5 inhibitors.
Several recent clinical trials have explored additional disease indications that might benefit from the vasodilatory properties of PDE5 inhibitors. A cream version of sildenafil has recently been tested in a phase II study examining female sexual arousal disorder (TABle 3) as well as in a study in which improved blood flow in patients with secondary Raynaud phenomenon was observed 142 . International consortiums are investigating the effects of sildenafil in intrauterine growth restriction, due to anticipated improvements in uteroplacental perfusion 143, 144 . Initial results suggest sildenafil improves fetal growth and maternal blood pressure across species, including human, sheep, rabbit and rodent 145, 146 . Several studies have also explored the effects of sildenafil, tadalafil or vardenafil in the context of metabolic disorders such as type 2 diabetes and obesity, assessing glucose tolerance and insulin signalling as well as effects on elevated body weight, nephropathy and cardiomyopathy (TABle 3) . Tadalafil improved insulin secretion, endothelial function and abdominal lean mass content in non-obese men 147 , and chronic sildenafil improved glycometabolic control, ameliorated visceral adiposity and prevented remodelling in diabetic cardiomyopathy [148] [149] [150] [151] . That said, vardenafil failed to reduce cardiovascular risk in men with type 2 diabetes 152 . Interestingly, the positive effects of sildenafil on adiposity and diabetic cardiomyopathy are suggested to be independent of sildenafil's vasodilatory properties, rather, being mediated by epigenetic signalling and/or a reduction of inflammatory chemokines [148] [149] [150] [151] . It is important to note, however, that one of the studies examining the effect of sildenafil on glucose homeostasis was terminated early due to safety concerns (TABle 2) . With regard to other indications related to nephropathy and cardiomyopathy, sildenafil has also been tested against contrast media-induced nephropathy, and tadalafil is being explored in the context of kidney stones and endocrine cardiomyopathy (TABle 3) . A meta-analysis of older clinical studies suggests PDE5 inhibitors could be an effective medical expulsive therapy for distal ureteral calculi, albeit not significantly improved relative to tamsulosin 153 . With regard to the brain, two early-stage clinical trials are testing the ability of sildenafil to reverse concussion-related reductions in cerebrovascular reactivity (TABle 3) .
As described for PDE4 inhibitors, numerous trials are exploring the therapeutic potential of PDE5 inhibitors as chemopreventives for solid tumours, multiple myeloma and head and neck squamous cell carcinoma. Early reports suggest that combining sildenafil with the chemotherapeutic regorafenib is safe in patients with solid tumours 154 . Further, numerous in vitro and animal NATuRE REvIEWS | DrUg DISCovEry 
PDE10 inhibitors.
Despite the PDE10 inhibitor clinical failures described above, TAK-063 was tested in healthy controls and patients with schizophrenia. In healthy controls, TAK-063 was reported to be safe and well tolerated 166 , altering the effects of ketamine on brain activity in healthy controls, particularly in the striatum, substantia nigra and ventrolateral prefrontal cortex (NCT01892189; accessed 28 May 2019). In patients with schizophrenia, although TAK-063 failed to demonstrate a significant effect on the total Positive and Negative Syndrome Scale score, there was a trend that mirrored effect sizes normally seen with risperidone 167 . Furthermore, TAK-063 did significantly improve numerous secondary endpoints relative to placebo 167 . It is not entirely clear why TAK-063 was able to succeed where PF-2545920 failed. Whereas one study suggested that TAK-063 activates the striatal direct and indirect pathways in a balanced manner and PF-254920 activates the direct pathway more so than TAK-063 (reF. 168 ), other studies have reported that PF-254920 activates these pathways equally 65, 169 . It is notable that TAK-063 -but not PF-254920 -increased sensorimotor gating in rodents as measured by prepulse inhibition of acoustic startle 168 , suggesting that prepulse inhibition of acoustic startle may more accurately predict antipsychotic-like effects of novel compounds. Preclinical studies are also exploring the therapeutic potential of PDE10 inhibitors in the context of l-DOPA-induced dyskinesias 170 and alcohol abuse disorders 133 .
Inhibition of PDE7, PDE8 or PDE11. Studies describ-
ing the physiological function of the PDE7, PDE8 and PDE11 families are now emerging; however, inhibitors have not yet reached the clinic. Like many of the PDE families discussed above, early research suggests that PDE7 and PDE8 inhibitors may have positive effects in diseases where cognition, neuroprotection, neuroinflammation and/or motor function are impaired models of colorectal cancer suggest that PDE5 inhibitors, either alone or as part of a multi-chemotherapeutic regimen, demonstrate an ability to prevent tumour growth (for example, see reFs 17, 154, 155 ) . Similarly, reports suggest tadalafil promotes tumour immunity in patients with head and neck squamous cell carcinoma 156, 157 (TABle 3) . However, particularly with regard to colorectal cancer, PDE5 inhibitors do not produce complete antitumori genic effects 16 . This lack of complete efficacy may be related to the fact that membrane guanylyl cyclases are inhibited in colorectal cancer 16 , and PDE5 may be primarily regulating cytosolic rather than membrane guanylyl cyclases 18, 19 . Alternatively, the overexpression of both PDE5 and PDE10A in colorectal cancer cells -the latter a membrane-enriched PDE 70,158 -may be involved 17 . Indeed, PDE10 inhibitors also inhibit growth of colorectal cancer cells 159, 160 ; however, when both PDE5 and PDE10 are inhibited, antitumor efficacy is improved in preclinical models 17 .
Although enthusiasm for PDE5 inhibitors as chemopreventives is growing 161 , it should be noted that PDE5 inhibitors similarly prevented prostate carcinogenesis in preclinical models but did not appear to reduce risk or recurrence in clinical studies 162 . Perhaps even more concerning, PDE5A appears to suppress mela noma cell invasion in mice 163 and a recent systematic review and meta-analysis showed that PDE5 inhibitors actually increase risk for melanoma and basal cell carcinoma in humans 164 .
PDE9 inhibitors.
Although PDE9 inhibitors thus far have failed in the clinic for brain diseases, they may hold therapeutic potential for cardiovascular diseases. In a mouse model of sickle cell disease, the PDE9 inhibitor BAY73-6691 exerted immediate benefits on acute vaso-occlusive events 165 , and a phase I clinical trial looking at safety, tolerability and pharmacokinetics/pharmacodynamics of the PDE9 inhibitor PF-04447943 in patients with sickle cell anaemia has recently been completed ( [171] [172] [173] [174] [175] . Similarly, PDE11 inhibitors may hold potential for treating age-related cognitive decline 71, 176 or as an adjunctive treatment to improve lithium responsiveness in patients with bipolar disorder 177, 178 . PDE7 inhibitors may also hold promise in treating leukaemia 179, 180 , and PDE8 inhibitors may have potential for treating disorders associated with reduced androgen production in males as PDE8 inhibitors, particularly when applied in combination with PDE4 inhibitors, stimulate Leydig cell steroidogenesis 181, 182 .
Therapeutic strategies beyond inhibition PDE activation
There are several disease states where PDE activation may be warranted. Tissue, brain region and subcellular domain-specific decreases in PDE expression/activity and/or increases in cyclic nucleotide signalling have been implicated in select disease states, including some age-related deficits 183, 184 , Huntington disease 185 , social isolation 186 , migrane [187] [188] [189] [190] [191] , retinitis pigmentosa 192 , infertility 99 , prostate cancer 193 , melanoma and basal cell carcinoma 164 , cardiac hypertrophy 24, 194 , acrodysostosis 25 and polycystic kidney disease 195 . PDE activators would be expected to have a greater impact in cells with higher cyclic nucleotide levels (either basal or stimulated) as opposed to cells with low cyclic nucleotide levels, although this remains to be empirically established. Indeed, Mironid have developed PDE4 longform-specific activators (mechanism as yet unknown; TABle 4) for the treatment of polycystic kidney disease where increased adenylyl cyclase activity caused by overexpression of vasopressin V2R receptors results in elevated cAMP levels that drive cyst growth and disease progression 196 . There are several natural mechanisms by which PDE activity can be activated (Fig. 3) , and it is our contention that these avenues could be manipulated pharmacologically to trigger PDE activation.
Targeting GAF domains. One route to PDE activation is by way of tandem GAF (cGMP-specific and stimulated PDE, Anabaena adenylyl cyclases and Escherichia coli FhlA) domains 197 (Fig. 3b ). Although GAF domains have been identified in over 7400 proteins, in mammals they are only found in the PDE 2, 5, 6, 10 and 11 families 198, 199 . For a vast majority of non-PDE GAF domains, the activating ligand is unknown; however, for PDEs it is known that cyclic nucleotides bind to these pockets (Fig. 3 ). PDE2 and PDE5 are activated when cGMP binds the GAF domain [200] [201] [202] , and PDE10 is activated by cAMP binding the GAF domain 203 . In the context of activation, binding of cyclic nucleotides to GAF domains is thought to cause structural changes that relieve autoinhibition of the PDEs (Fig. 3) . In contrast, cGMP binding the GAF-A domain of PDE6 enhances protein-protein interactions that inhibit PDE6 catalytic activity 204 . This suggests that blocking cGMP binding of the PDE6 GAF domain may provide a means of promoting PDE6 activity. This also suggests it may be possible to both activate and inhibit GAF-containing PDEs with small molecules at a site distinct from the catalytic domain. Indeed, PDE11A is activated when a cGMP analogue -but not cGMP itself -binds the GAF domain 203 . Further, even though cGMP binding of the GAF domain activates PDE5 (reF. 200 ), several other types of molecule that bind the GAF domain inhibit PDE5 in its activated -but not basal -state 205 . This is consistent with the fact that GAF domains are known to bind a diverse array of small molecules that are unrelated to cyclic nucleotides 197 . The fact that GAF domains are only found in PDEs in mammals 199 makes GAF domains of high interest in the context of drug targeting 206 . Importantly, mammalian GAF domains are sufficiently structurally divergent from one another (for example, low degree of homology between PDE families and the tandem GAF domains are preceded by variable N-terminal stretches) to allow selective pharmacological targeting of individual PDE families 200 . Together, these observations suggest that the GAF domains may provide an inroad for targeting reagents that selectively activate a given PDE isoform while avoiding off-target activity.
Preventing trans-capping. PKA or protein kinase G (PKG) phosphorylation of PDE3 (reFs 207, 208 ), PDE4 (reFs 207, 209 ), PDE5 (reF. 210 ) and PDE8 (reF. 211 ) is also known to activate catalytic activity in a negative feedback loop. In the case of PDE4, for example, catalytic activity is inhibited when the UCR2 regulatory domain 'trans-caps' the catalytic site, thus occluding cAMP from reaching the enzymatic core of PDE4 (reFs 73,212 ) ( Fig. 3c ). PKA phosphorylation of the UCR1 regulatory domain blocks the ability of UCR2 to trans-cap the catalytic site, which locks PDE4 in the active state 73 . Notably, select PDE4D inhibitors allosterically inhibit catalytic activity by promoting 'trans-capping' 130 , whereas phosphatidic acid activates PDE activity by inhibiting trans-capping in a similar but mutually exclusive manner to PKA [213] [214] [215] . Furthermore, the dominant negative peptide 'UCR1C' , which corresponds to the UCR1 sequence, also activates PDE4 activity by inhibiting trans-capping 216 . These results provide proof of principle that activation of PDE4 may be achieved by either small molecules or biologics that prevent UCR2 from adopting a trans-capping conformation.
Manipulating protein-protein binding. PDEs may also be activated by manipulating protein-protein binding interactions. PDE6 is unique in the fact that the heterodimeric holo-enzyme includes two inhibitory subunits that span the catalytic pockets of the dimer, thus occluding cGMP from the catalytic site 217 (Fig. 3d ). Binding of the GTP-bound α-subunit of the hetero trimeric G-protein transducin relieves PDE6 inhibition by binding to the C-terminal region of PDE6 and its inhibitory subunits 218 . The full crystal structure of PDE6 is not yet available 219 ; however, recent cryo-EM work 220 has confirmed the predicted structural organization of the holo-enzyme, albeit without sufficient detail to inform pharmacological targeting. The success in upregulating PDE6 activity via gene transfer to combat retinitis pigmentosa 192 (see following section) suggests that PDE6 activation could be a viable therapeutic strategy for the treatment of vision loss. As discussed in greater detail below, it may also be possible to increase PDE activity
Retinitis pigmentosa
A rare genetic disorder characterized by black pigmentation and retinal degeneration.
Trans-capping
The process whereby the regulatory domains from one phosphodiesterase (PDe) enzyme physically bind -and, thus, block substrate access to -the C-terminal catalytic domain of another PDe molecule. by preventing the binding of PDEs to binding partners that sequester or suppress activity.
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Gene therapy
Viral transfer of PDE genes, agents that silence PDE gene expression (for example, antisense, silencing or microRNAs) 163, [221] [222] [223] [224] [225] or gene editing (for example, CRISPR-Cas9) 226 might also prove a useful means of therapeutically targeting individual PDE isoforms (Fig. 4) . The best-characterized PDE gene therapy approach to date targets PDE6 activity in the retina. A loss of transducin-mediated activation of PDE6 results in elevated cGMP levels, which causes the loss of primary rods and, ultimately, vision 227 . Expression of recombinant PDE6α in the retina via an adeno-associated virus (AAV-PDE6α) preserved retinal structure, phototransduction and vision in retinal degeneration mice, as did AAV-PDE6β 228, 229 . AAV-PDE6α similarly rescued retinal deficits in a mouse model that mimics human retinitis pigmentosa mutations 230 . Experiments injecting AAV-PDE6γ into the retina have also proven successful in mice 231 . In dogs, delivery of recombinant PDE6α using a tyrosine capsid-mutant AAV8 was able to stabilize cGMP levels and improve survival of photoreceptor rods and cones in PDE6α-mutant dogs; however, several adverse effects related to the AAV injection were identified 192 . The recent development of synthetic AAV vectors that target the retina in non-human primates may provide the answer to these problems in the future 232 . Notably, two clinical trials are underway testing the safety and efficacy of PDE6 gene therapy in retinitis pigmentosa (phase I NCT02759952 and phase II NCT03328130; accessed 29 May 2019). A rapidly evolving approach within the gene therapy field is optogenetic medicine, which combines viral delivery of recombinant, light-activated proteins with biomedical devices that emit light of the specific intensity and wavelength needed to activate those proteins 233 . With the field of personalized bioelectronic implants quickly evolving, optogenetic-based biomedical approaches are being pursued for neurological diseases, cancer, cardiovascular disease and metabolic disorders 233 . Given that optogenetic-based approaches have now entered clinical trials 233 , it is worth noting here that light-activated PDEs have been identified in lower organisms [234] [235] [236] and engineered in the laboratory 237 . Both are being explored as biological tools in higher organisms. Activating or inhibiting a given PDE by a spatially and temporally restricted light emission, as opposed to a systemically administered pharmacological agent, may prove an ideal approach for treating diseases where cyclic nucleotide signalling is downregulated in one tissue yet upregulated in another (for example, ageing; see reF. 238 ). This technique might also provide a means of avoiding side effects associated with targeting PDE activity in a specific tissue (for example, nausea/emesis associated with inhibiting PDE4 in the area postrema). Given the vast diversity of phosphodiesterase (PDE) isoforms, each with unique tissue expression profiles, subcellular compartmentalization and protein-protein interactions, it is becoming clear that selective targeting of PDE function will be required to achieve efficacy while diminishing undesirable side effects. Small-molecule inhibitors (for example, cilomilast) are readily developed with family-specific selectivity (for example, targeting PDE4 over PDE3); however, isoform specificity remains a challenge (for example, cilomilast inhibits PDE4D with only sevenfold selectivity versus PDE4B) 326 . Conversely , gene therapy (that is, expressing a recombinant construct to knock down or restore expression of a given PDE isoform) and dominantnegative approaches (that is, expressing a catalytically inactive PDE4D5 that displaces the endogenous isoform from its interacting partners) can target isoform subtypes exclusively (for example, targeting PDE4D5 but not PDE4D3 nor PDE4B). That said, dominant-negative approaches would influence signalling within all microdomains regulated by that isoform. The greatest specificity can be achieved with peptide/small-molecule binding disruptors or mutagenesis approaches (not shown) that are designed to prevent a specific PDE isoform from binding a specific partner, thus altering signalling only within one specific complex. As shown here, a disruptor peptide that specifically prevents the interaction between PDE4D5 and β-arrestin would lead to the recruitment of EPAC1 to β2 adrenergic receptors (β2-AR), but would leave PDE4D5 regulation of heat shock protein 20 (HSP20) and RACK1 complexes intact 239, 327, 328 . EPAC, exchange protein activated by cAMP.
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Targeting location
As production of cAMP is utilized by various different Gs-coupled receptors to transduce signals, compartmentalization of signalling intermediates is crucial to define physiological outcomes specific to each receptor 239 . This compartmentalization of cyclic nucleotide signalling is achieved by virtue of PDEs being tethered to a precise cellular location via binding partners ( Supplementary  Table 1 ). Thus, promoting or disrupting isoform-specific protein-protein interactions may prove a viable approach to therapeutically target PDEs in an isoform-specific manner, a level of specificity that has not been achieved with pharmacological inhibitors to date (Fig. 4) .
Dominant-negative PDEs.
Proof of principle for such an approach first emerged with studies using dominant-negative PDEs (DN-PDEs), which are catalytically inactive mutants that would displace their endogenous PDE. Using specific DN-PDE4 isoforms, in vitro studies have successfully altered perinuclear cAMP signalling 240 , β-arrestin-dependent desensitization of the β2-adrenergic receptor 241, 242 , growth control of prostate cancer cells 193 , prostanoid receptor-mediated cAMP signalling 243 , glucagon-like peptide-1 release 244 and cAMP gradients at the centrosome 245 . DN-PDE4 tools have also yielded beneficial effects in vivo. For example, viral delivery of a DN-PDE4A5 to the mouse hippocampus was able to rescue localized cAMP signalling deficits and hippocampus-dependent memory impairments that were caused by sleep deprivation [246] [247] [248] . In contrast, overexpression of a DN-PDE4B1 in the forebrain of mice did not affect hippocampus-dependent memory, although it did enhance hippocampal long-term potentiation in male mice 249 . This finding underscores the importance of understanding the role of specific PDE isoforms, because a homozygous mutation in PDE4B (Y358C) that greatly reduces activity of all PDE4B isoforms by virtue of attenuating interactions with the scaffold protein disrupted in schizophrenia 1 (DISC1) improves both long-term potentiation and memory as well as other mood-related behaviours 250 . It is interesting to note that nature has developed its own dominant-negative approach with PDE4A7, a PDE isoform that is targeted to specific subcellular compartments but is catalytically dead 251 .
One point to consider in adopting a dominantnegative approach is the fact that a single PDE isoform can contribute to more than one function in a cell via its participation in multiple distinct signalling complexes, which involve mutually exclusive protein-protein interactions 252 (Supplementary Table 1 ; Fig. 4 ). For instance, PDE4D5 is involved in numerous processes common in almost all cells, such as cell growth, cell orientation, desensitization of Gs-coupled receptors and inactivation of the phosphorylation of the ubiquitous chaperone HSP20 (reF. 253 ). The ability for PDE4D5 to have all these functions in a cell is a result of it being localized in different compartments by different anchors (for example, RACK1 at the leading edge of cells, β-arrestin at transmembrane receptors and HSP20 in the cytosol 253 ; Fig. 4 ). It is clear that this is also the case for several other isoforms based on proven protein-protein binding interactions (for example, in heart tissue/cells, PDE4D3 can bind to either the ryanodine receptor, HSP20 or an AKAP9/potassium channel complex; see Supplementary Table 1 ) or based on inference from the fact that the exact same isoform can be found localized to multiple subcellular domains (for example, ~50% of PDE11A4 in neurons localizes to the cytosol whereas 25% is localized to the nuclear fraction and another 25% to the membrane compartment 70 ). Thus, a non-selective dominant-negative approach has the potential to influence multiple domains within the cell. To achieve a compartment-specific manipulation of a given PDE isoform, one could mutate the binding sites that mediate a particular protein-protein interaction. Mutating isoform-specific binding sites has also proven a useful approach, revealing that an integrin α5-PDE4A5 complex regulates endothelial inflammation 254 , a PDE3A1-SERCA complex regulates myocardium contractility 255 and a DISC1-mediated sequestering of PDE4B regulates hippocampal function 250 . An alternative approach is to develop a peptide or small molecule that specifically competes for a given protein-protein binding site 256 . This approach would displace only a specific 'pool' of a given PDE isoform, leaving the vast remainder unfettered in their respective signalling com plexes ( Fig. 4 ). Efforts have begun to identify small molecules capable of promoting or interfering with protein-protein interactions, but the results have not yet been published so it is too early to speculate on the required design characteristics at this stage.
Disrupting protein-protein interactions with peptides.
A recent review suggests cell-permeable peptide disruptors effectively manipulate specific PDE isoforms in a compartment-specific manner 256 , and evidence continues to build. More recently, a PDE4D-FAK disrupting peptide prevented direction sensing and invasion of melanoma cells 257, 258 and a PDE8A-Raf1 disruptor retarded cancer cell growth promoted by a Ras mutation 211 . Interestingly, the same PDE8A-Raf1 peptide has also been used to target T cell adhesion and migration and was more potent than a PDE8-specific inhibitor in reducing inflammatory signalling 257 . The effectiveness of PDE displacement has also been demonstrated in vivo, where intraperitoneal injections of a PDE4-HSP20 disruptor significantly attenuated hypertrophy-induced cardiac remodelling 259 .
Disrupting PDE homodimerization.
Disrupting PDE homodimerization (that is, a PDE monomer binding to itself) may also prove an effective way to target PDE function in a domain-specific manner. Disrupting PDE11A4 homodimerization using a peptide recognizing its GAF-B domain was shown to selectively remove PDE11A4 from membrane-bound complexes but not the cytosol, which may hold utility for improving responsivity to the mood stabilizer lithium 177 or age-related cognitive decline 71, 176 . Conversely, a peptide or mutation that could stabilize PDE11A4 homodimerization might prove useful in treating the deleterious psychological effects of social isolation 186 . Targeting homodimerization of PDE2, PDE4 or PDE5 may also relocate the enzymes by virtue of changing susceptibility to regulatory post-translational modifications (PTMs) 199, 260 .
Indeed, nature appears to have taken advantage of dimerization as a mechanism to regulate PDE trafficking. For example, when PDE10A2 heterodimerizes with PDE10A19, PDE10A2 is prevented from trafficking to the membrane as it normally does under conditions of homodimerization 261 . Such complex-specific targeting of PDE function may be required to achieve efficacy in the absence of unwanted side effects, particularly in cases where multiple subfamily isoforms orchestrate various physiologic responses by virtue of different protein-protein interactions (for example, targeting various PDE3 isoforms for cardiovascular disease 262 ).
Targeting post-translational modifications
As PTMs directly regulate PDE activity and location, PTMs could be considered a point of therapeutic control ( Fig. 5 ).
Phosphorylation. PKA or PKG phosphorylation of PDE3 (reFs 207, 208 ), PDE4 (reFs 207, 209 ), PDE5 (reF. 210 ) and PDE8 (reF. 211 ) will stimulate catalytic activity. Phosphorylation can also influence PDE cellular location by virtue of preventing other PTMs that promote membrane association (for example, palmitoylation) or changing protein-protein binding interactions. A great example to illustrate these principals is PDE10A2. PDE10A2 is palmitoylated in its N-terminal region, which directs membrane targeting and trafficking to dendrites 158 . If, however, PDE10A2 undergoes isoform-specific phosphorylation by PKA on Thr16 (reF. 263 ), palmitoylation of PDE10A2 is attenuated and the specific membrane localization is lost 158 . Interestingly, phosphorylation on the same site also interferes with the scaffolding of PDE10A2 by AKAP150 (reF. 264 ). Hence, although PDE10A catalytic activity is not directly affected by this PTM, cyclic nucleotide levels should increase within this compartment due to the absence of PDE10A2. Preliminary evidence also suggests that PDE11A4 can similarly be shuttled between membrane and cytosolic compartments by virtue of phosphorylation of N-terminal serines, although this is likely by virtue of altering proteinprotein interactions as opposed to a direct insertion into the membrane 265 . PKA phosphorylation of PDE4D3 drives an association with the mAKAP signalling complex to evoke rapid signal termination in the muscle compartment 266 , which may have therapeutic implications given that polymorphisms in the PDE4D3-mAKAP binding site lead to a higher susceptibility to cardiovascular disease 267 . PDE4D enzymes also get phosphorylated by both casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β) in the catalytic region on a motif known as a 'phosphodegron' 268 . This action increases the affinity of the PDE for a ubiquitin ligase complex (cullin 1 containing SCF E3 ligase) which promotes proteosomal degradation of the enzyme 268 . Hence, PDE phosphorylation not only affects activity, localization and protein-protein interactions but also regulates protein turnover.
Ubiquitylation and SUMOylation. It has been known for some time that increases in PKA activity promote the proteosomal degradation of short-lived proteins, an action that can be enhanced by PDE inhibitors 269 .
However, we are just starting to understand that the stability of PDEs can themselves be influenced by the ubiquitin-proteosome system (Fig. 5 ). Ubiquitin conjugation is known to target proteins for degradation by the proteasome and specificity is introduced at the level of E3 ligase-substrate interaction. We now know of multiple instances where PDEs interact definitively with one of the over 600 E3 ligase types to dramatically shorten the PDE half-life and this could be a new point at which to direct innovative therapeutics. As mentioned above, PDE4Ds can be degraded by virtue of the SCF E3 (reF. 268 ), whereas PDE4B levels can be downregulated by a different E3, Smurf2, to promote anti-fibrotic signalling in the liver 270 . PDE4D5 can also be targeted for ubiquitin modification by the RING-type MDM2 E3 ligase; however, this β-adrenergic-driven ubiquitylation of PDE4D does not signal a degradation of the enzyme. Instead, it shifts PDE4 from binding RACK1 to binding β-arrestin 271 . PDE4s are similarly regulated by the ubiquitin-like protein SUMO (small ubiquitin-like modifier) 272 . SUMO conjugation tends to alter the location, activity or protein-protein interactions of a protein rather than tagging for destruction via the ubiquitinproteosome system 273 . Unlike ubiqui tylation, sites of SUMOylation can be predicted in the amino acid sequence of putative substrates as conjugation usually occurs on a lysine residue within the consensus h-K-X-D/E (where h is a bulky hydrophobic and X is any residue) 273 . PDE4s from subfamilies A and D contain the consensus motif, whereas subfamilies B and C do not. This adds an extra layer of subfamilyspecific regulation as SUMOylation serves both to protect against the inhibitory phosphorylation by extracellular signal-regulated/mitogen-activated protein kinases 274 
S-nitrosylation and proline hydroxylation.
Two additional PTMs that trigger PDEs for destruction include S-nitrosylation and proline hydroxylation (Fig. 5 ). PDE5 can be S-nitrosylated by nitric oxide on Cys220 (reF. 275 ), which targets the enzyme to the proteasome and reduces PDE activity. Under conditions of reduced nitric oxide bioavailability, as in heart disease, PDE5 is upregulated due to a loss of this S-nitrosylation-induced degradation 275 . Proline hydroxylation has also been identified as a modification that can tag substrates for recognition by E3 ligase complexes 276 . In the heart, proline hydroxylase domain-containing proteins hydroxylate surface-associated prolines on PDE4D enzymes, triggering their degradation 277 . In this way, direct binding of proline hydroxylase domain-containing proteins to PDE4s increases cAMP without affecting adenylyl cyclase activity.
Challenges
Although this is clearly an exciting time in the PDE field, much work remains to be done. For therapeutics to be efficiently developed, we need to more thoroughly understand precisely where cyclic nucleotide signalling is disrupted in a given disease -in which tissue, cell types Phosphodegron A phosphorylation motif that alters the rate of degradation by attracting ubiquitin ligases to the phosphorylated protein.
www.nature.com/nrd and subcellular compartments. We then need to target a PDE in a defined locale, with the understanding that subcellular compartmentalization of a given PDE may vary depending on species, age, tissue type or disease status (for example, see reFs [5] [6] [7] [8] [9] [10] [11] [12] ; for a full review, see Supplementary Table 1 ). This consideration is equally important in the evaluation of potential efficacy and potential side effects. To maximize potential efficacy while minimizing potential side effects, one would target a PDE that is enriched, if not exclusively expressed, in the tissue of interest and that controls the same pool of cyclic nucleotides that is altered by the disease. At the Cyclic nucleotide dynamics can be modulated by the addition of different functional groups to phosphodiesterases (PDEs). Phosphorylation is a very common mechanism to control PDE activity as depicted by the action of protein kinase A (PKA) on PDE4D3. Both enzymatic activity and binding affinity of PDE4D3 for mAKAP are increased by PKA phosphorylation, allowing a faster signal termination in myocytes 266 . Palmitoylation of PDE10A2 in its N-terminal region translocates the enzyme to the plasma membrane, although its phosphorylation by PKA can prevent the action of the palmitoyl acyltransferase (zDHHC) 158 . Ubiquitylation can influence PDE function by controlling stability. For example, the E3 ubiquitin ligase Smurf2 targets PDE4B for degradation which leads to the attenuation of liver fibrosis 270 . S-Nitrosylation can also tag PDEs for destruction. Thus, the covalent incorporation of nitric oxide (NO) to the GAF-A domain of a protein kinase G (PKG)-phosphorylated and active PDE5 directs the enzyme to the proteasome 275 . Hydroxylation of proline residues has emerged as another post-translational modification to stimulate turnover of PDEs. Prolyl hydroxylase domain protein 2 (PHD2) action on PDE4D increases its recognition by E3 ligase complexes in cardiomyocytes 277 . Finally , SUMOylation can intensify the activity of PDE4A and PDE4D. The small ubiquitin-like modifier (SUMO) transfer from the E2 conjugase UBC9-E3 enzyme PIASy complex to the PDEs enhances their activation by PKA phosphorylation and represses their inhibition induced by extracellular signal-regulated kinase (ERK) activity 272 . same time, efforts to unravel the intramolecular signals responsible for trafficking each PDE also need to continue to inform more sophisticated therapeutic approaches that can preferentially target a given PDE in a given subcellular compartment. Along these same lines, we need to grow our understanding of how to stimulate PDE activity and how to target the PDE catalytic activity of dual-specificity PDEs in a functionally selective manner (that is, target only its cAMP or cGMP-hydrolytic activity; see reF. 206 for further discussion). Perhaps by increasing the specificity of our approach, we can retain efficacy while mitigating the numerous side effects described above that have plagued PDE inhibitors to date.
An additional challenge is to gain a better understanding of which physiological/disease processes are governed by PDE regulation of canonical versus non-canonical cyclic nucleotides. Research into the role of non-canonical cyclic nucleotides is rapidly evolving as new techniques and reagents facilitate functional studies 4 . cCMP and cUMP are synthesized by soluble guanylate and soluble adenylyl cyclases in mammalian systems, although an as-yet-to-be identified generator likely accounts for the majority of production given the dissociation between soluble guanylyl cyclase/soluble adenylyl cyclase and cCMP/cUMP expression patterns 4 . ExoY, a bacterial nucleotidyl cyclase, is known to generate cUMP in non-mammalian systems 2 . Hydrolysis of cCMP is catalysed by PDE7A whereas cUMP is broken down by PDE3A, PDE3B and PDE9A 2 . Functionally, both nucleotides have been shown to activate PKA/PKG 278 and cyclic nucleotide gated channels 279 , and cCMP is described as a partial agonist of EPAC 280 . In a disease context, the non-canonical cyclic nucleotides play roles in promoting virulence of pseudomonas aeruginosa infections 281 and triggering apoptosis of cancer cells 282 ; however, much more research is needed to accurately characterize the pathophysiology involving these signalling molecules. Difficult issues facing the field will be defining specific non-canonical cyclic nucleotide signalling systems that are aberrantly regulated in disease, determining the mechanisms by which PDEs might preferentially degrade non-canonical versus canonical cyclic nucleotides, and visualizing the compartmentalization of non-canonical signalosomes in specific locations within cells and tissues.
Finally, the development of PDE-targeted therapeutics faces the same challenge as does all drug discovery -the high rate of failure in clinical trials. A recent study suggests that from 2000 to 2015, only 13.8% of all compounds made it from phase I to approval 283 . When considering success rates for individual indications, we may gain insight into the likelihood that a PDE-targeted therapeutic will achieve success within a given disease area. For example, oncology saw only 3.4% of compounds make it from phase I to approval, perhaps not surprising given the resistance and heterogeneity that dogs this area. In contrast, metabolic/endocrinology, cardiovascular, CNS, autoimmune/inflammation, genitourinary and ophthalmology saw a success rate of 19.6%, 25.5%, 15%, 15.1%, 21.6% and 32.6%, respectively 283 . This certainly paints a grim picture for pursuing any type of therapeutic in the context of cancer; however, this failure rate also underscores the desperate need to develop novel therapeutic options. It is then important to note that success rates were doubled for cancer compounds when patient selection biomarkers were employed in the trials; the success rate for cardiovascular compounds similarly benefited 283 . Importantly, expression or activity of PDEs themselves may prove viable biomarkers in this context (Box 2).
Outlook
Although the challenge of targeting localized pools of PDEs for purposes of correcting pockets of aberrant cyclic nucleotide signalling has proved difficult in the past, there are indications that innovative approaches and technological advances are making headway (see TABle 4 for recent patent activity that includes PDE activators, biomarkers and viral approaches). For example, agents that show remarkable selectivity for subfamilies of PDE4 are showing promising results in mouse models of learning and memory, and translation to human disease would be a game-changing advance 124 . Additionally, novel delivery systems are being developed that can transport PDE inhibitors to precise tissues or cell types, thereby abrogating complications associated with systemic distribution (for example, see reFs 284, 285 ). In the future, novel delivery systems such as these could be employed to deliver agents that specifically disrupt the anchoring of single isoforms. Another potential approach is the intelligent design of a new generation of PDE inhibitors that preferentially accumulate in or segregate from certain tissues or organs. The mild side-effect profile of apremilast is largely due to its inability to penetrate the brain and engineering of similarly restricted distribution profiles may unlock the latent abilities of other PDE inhibitors. Gene therapy that seeks to abrogate or enhance activity of single PDE isoforms in a cell type-specific manner may provide a way to combat disease or fight complications associated with ageing. There is also the possibility that an improved therapeutic window might be achieved by combining suboptimal doses of PDE inhibitors with ineffective doses of downstream-target activators, which would result in an effective combined dose only in tissues and subcellular compartments where both molecules were present (for example, see reF. 286 ). Indeed, PKA, PKG and Epacs have been implicated as therapeutic targets in their own right for numerous indications for which PDE inhibitors are being pursued, including diseases of the cardiovascular, immune, metabolic and nervous systems as well as cancer (for example, see reFs 116, 117, [287] [288] [289] [290] [291] [292] . Further, several studies in various tissues have attributed the beneficial effects of PDE inhibitors to the activation of PKA, PKG and/or Epac (for example, see reFs 124, [293] [294] [295] ). As we learn more about the functional role and molecular interactions of each PDE splice variant, and how the function and/or localization of an individual variant may be altered in a given disease, it will become clearer how we can successfully target PDEs in a specific fashion to achieve efficacy while avoiding side effects. Only with this detailed level of knowledge will we be able to realize the full potential of PDEs as therapeutic targets.
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